Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06762964

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

Cardiac and Metabolic Effects of Dapagliflozin in the Failing Fontan Circulation: A Phase II, Prospective, Double-Blind Study

Sponsor: Mayo Clinic

Conditions Fontan Circulation HFpEF - Heart Failure With Preserved Ejection Fraction Single Ventricle Heart Disease

Interventions Dapagliflozin tablet Placebo Tablet

Updated 4 times since 2025 Last updated: Sep 29, 2025 Started: May 16, 2025 Primary completion: Feb 28, 2027 Completion: Feb 28, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Fontan Circulation and HFpEF - Heart Failure With Preserved Ejection Fraction, this trial is actively recruiting participants. The trial is conducted by Mayo Clinic and has accumulated 4 data snapshots since 2025. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

4 versions recorded

Nov 2025 — Present [monthly]

Recruiting PHASE2
Jun 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Apr 2025 — Jun 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Feb 2025 — Apr 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States